このアイテムのアクセス数: 32

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s41409-025-02508-2.pdf1.58 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorOshima, Shinichiroen
dc.contributor.authorArai, Yasuyukien
dc.contributor.authorKondo, Tadakazuen
dc.contributor.authorYano, Shingoen
dc.contributor.authorHirabayashi, Shigekien
dc.contributor.authorUchida, Naoyukien
dc.contributor.authorOnizuka, Makotoen
dc.contributor.authorMiyakoshi, Shigesaburoen
dc.contributor.authorTanaka, Masatsuguen
dc.contributor.authorTakahashi, Satoshien
dc.contributor.authorHayashi, Masayukien
dc.contributor.authorKawakita, Toshiroen
dc.contributor.authorUehara, Yasufumien
dc.contributor.authorOta, Shuichien
dc.contributor.authorIzumi, Toruen
dc.contributor.authorSawa, Masashien
dc.contributor.authorNishida, Tetsuyaen
dc.contributor.authorKatayama, Yutaen
dc.contributor.authorNagafuji, Kojien
dc.contributor.authorKato, Kojien
dc.contributor.authorIchinohe, Tatsuoen
dc.contributor.authorAtsuta, Yoshikoen
dc.contributor.authorYanada, Masamitsuen
dc.date.accessioned2025-03-14T01:53:58Z-
dc.date.available2025-03-14T01:53:58Z-
dc.date.issued2025-01-
dc.identifier.urihttp://hdl.handle.net/2433/292491-
dc.description.abstractUmbilical cord blood transplantation (CBT) is accepted as an effective treatment for acute myeloid leukemia (AML), and reduced-intensity conditioning (RIC), rather than myeloablative conditioning (MAC) regimens allowed elderly patients to be treated safely. However, appropriate intensities of conditioning regimens are still unclear, especially for middle-aged patients. To compare outcomes after RIC and MAC regimens, we analyzed AML patients aged 16 years or older in the Japanese registry database, who underwent single cord unit CBT between 2010-2019. Median ages of the RIC group (n = 1353) and the MAC group (n = 2101) were 59 and 51 years (P < 0.001), respectively. 5-year overall survival (OS) after MAC was superior to that of RIC (38.3% vs 27.7%, P < 0.001) with lower incidence of relapse (33.9% vs 37.4%, P = 0.029) and better neutrophil engraftment (84.7% vs 75.9%, P < 0.001). Detailed subgroup analysis revealed that age at transplantation is the most important factor affecting 5-year OS in RIC and MAC. This analysis identified a threshold of 55 years, beyond which the superiority of MAC disappeared, irrespective of other factors such as disease status or performance status. In conclusion, RIC may be preferable for patients aged 56 or older in CBT for AML due to higher potential toxicities.en
dc.language.isoeng-
dc.publisherSpringer Natureeni
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.en
dc.rights© The Author(s) 2025en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/.-
dc.subjectHaematopoietic cell growth factorsen
dc.subjectRisk factorsen
dc.titleMyeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55en
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleBone marrow transplantationen
dc.relation.doi10.1038/s41409-025-02508-2-
dc.textversionpublisher-
dc.identifier.pmid39838078-
dcterms.accessRightsopen access-
dc.identifier.pissn0268-3369-
dc.identifier.eissn1476-5365-
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons